LITHIUM CARBONATE- lithium carbonate tablet

Nchi: Marekani

Lugha: Kiingereza

Chanzo: NLM (National Library of Medicine)

Viambatanisho vya kazi:

LITHIUM CARBONATE (UNII: 2BMD2GNA4V) (LITHIUM CATION - UNII:8H8Z5UER66)

Inapatikana kutoka:

West-Ward Pharmaceutical Corp

INN (Jina la Kimataifa):

LITHIUM CARBONATE

Tungo:

LITHIUM CARBONATE 300 mg

Njia ya uendeshaji:

ORAL

Dawa ya aina:

PRESCRIPTION DRUG

Matibabu dalili:

Lithium Carbonate Tablets, USP are indicated in the treatment of manic episodes of Bipolar Disorder. Bipolar Disorder, Manic (DSM-III) is equivalent to Manic Depressive illness, Manic, in the older DSM-II terminology. Lithium Carbonate Tablets, USP are also indicated as a maintenance treatment for individuals with a diagnosis of Bipolar Disorder. Maintenance therapy reduces the frequency of manic episodes and diminishes the intensity of those episodes which may occur. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, aggressiveness, and possibly hostility. When given to a patient experiencing a manic episode, lithium may produce a normalization of symptomatology within 1 to 3 weeks. Lithium should generally not be given to patients with significant renal or cardiovascular disease, severe debilitation or dehydration, or sodium depletion, and to patients receiving diuretics, since the risk of lithium toxicity

Bidhaa muhtasari:

Lithium Carbonate Tablets, USP 300 mg are supplied as Round, White Scored Tablets; Debossed "WW" and "300" under the score.     Bottles of 100 Tablets     Bottles of 1000 Tablets     Unit Dose Boxes of 100 Tablets Store at 20-25ºC (68-77ºF) [See USP Controlled Room Temperature]. Protect from moisture. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Manufactured by: West-ward Pharmaceutical Corp. Eatontown, NJ 07724 Revised December 2011

Idhini hali ya:

Abbreviated New Drug Application

Tabia za bidhaa

LITHIUM CARBONATE- LITHIUM CARBONATE TABLET
WEST-WARD PHARMACEUTICAL CORP
----------
LITHIUM CARBONATE TABLETS, USP
RX ONLY
REV. 12/11
WARNING
Lithium toxicity is closely related to serum lithium levels, and can
occur at doses close to
therapeutic levels. Facilities for prompt and accurate serum lithium
determinations should be
available before initiating therapy (see DOSAGE AND ADMINISTRATION).
DESCRIPTION
Each Lithium Carbonate Tablet, USP for oral administration contains
300 mg of Lithium Carbonate.
INACTIVE INGREDIENTS
Lithium Carbonate Tablets, USP contain the following inactive
ingredients: Magnesium Stearate,
Microcrystalline Cellulose, Polyvinylpyrrolidone, Sodium Lauryl
Sulfate, and Sodium Starch
Glycolate.
Lithium is an element of the alkali-metal group with atomic number 3,
atomic weight 6.94, and an
emission line at 671 nm on the flame photometer.
Lithium acts as an antimanic.
Lithium Carbonate is a white, light, alkaline powder with molecular
formula Li
CO and molecular
weight 73.89.
CLINICAL PHARMACOLOGY
Preclinical studies have shown that lithium alters sodium transport in
nerve and muscle cells and effects
a shift toward intraneuronal metabolism of catecholamines, but the
specific biochemical mechanism of
lithium action in mania is unknown.
INDICATIONS AND USAGE
Lithium Carbonate Tablets, USP are indicated in the treatment of manic
episodes of Bipolar Disorder.
Bipolar Disorder, Manic (DSM-III) is equivalent to Manic Depressive
illness, Manic, in the older
DSM-II terminology.
Lithium Carbonate Tablets, USP are also indicated as a maintenance
treatment for individuals with a
diagnosis of Bipolar Disorder. Maintenance therapy reduces the
frequency of manic episodes and
diminishes the intensity of those episodes which may occur.
Typical symptoms of mania include pressure of speech, motor
hyperactivity, reduced need for sleep,
flight of ideas, grandiosity, elation, poor judgment, aggressiveness,
and possibly hostility. When given
to a patient experiencing a manic episode, lithium may produce a
normali